SEC Comment Letter 0000000000-25-003770 to LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Date: April 8, 2025 · CIK: 0001335105 · Accession: 0000000000-25-003770
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286385
Letter
Re: Lixte Biotechnology Holdings, Inc. Registration Statement of Form S-1 Filed April 4, 2025 File No. 333-286385 Dear Bastiaan van der Baan:
April 8, 2025
Bastiaan van der Baan Chief Executive Officer Lixte Biotechnology Holdings, Inc. 680 East Colorado Boulevard, Suite 180 Pasadena, CA 91101
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: David L. Ficksman, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 8, 2025 Bastiaan van der Baan Chief Executive Officer Lixte Biotechnology Holdings, Inc. 680 East Colorado Boulevard, Suite 180 Pasadena, CA 91101 Re: Lixte Biotechnology Holdings, Inc. Registration Statement of Form S-1 Filed April 4, 2025 File No. 333-286385 Dear Bastiaan van der Baan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David L. Ficksman, Esq. </TEXT> </DOCUMENT>